Genitourinary Cancer Research Review Issue 27
In this issue:
Survival benefit to disitamab vedotin plus immunotherapy in bladder cancer
Durvalumab-BCG improves DFS in resected NMIBC
Neoadjuvant TAR-200 + cetrelimab promising for MIBC
Renal dysfunction does not mitigate efficacy of EV + pembrolizumab in UC
KEYMAKER-U03 substudy: Novel front-line triplets for ccRCC
Ultra-hypofractionated radiotherapy non-inferior for localised prostate cancer
Post-ICI lenvatinib plus everolimus bests cabozantinib for progressive ccRCC
Promising activity for sac-TMT in pre-treated advanced UC
High-dose chemotherapy improves prognosis in multiply relapsed germ cell tumors
Erdafitinib ± cetrelimab for cisplatin-ineligible FGFR-altered UC
Expert contributor
Associate Professor Andrew Weickhardt
Associate Professor Andrew Weickhardt is a medical oncologist at the Olivia Newton-John Cancer and WellnessCentre in Melbourne. He has an interest in using immunotherapy and personalised treatments for patients with genitourinary cancer. He is actively involved in translational research investigating biomarkers of response andresistance to these treatments, and is involved in several phase 1 trials […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.